Skip to main content
Erschienen in: International Journal of Clinical Oncology 3/2016

16.10.2015 | Original Article

Proposal for selection criteria of secondary cytoreductive surgery in recurrent epithelial ovarian, tubal, and peritoneal cancers

verfasst von: Takeo Minaguchi, Toyomi Satoh, Koji Matsumoto, Manabu Sakurai, Hiroyuki Ochi, Mamiko Onuki, Akinori Oki, Hiroyuki Yoshikawa

Erschienen in: International Journal of Clinical Oncology | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

The selection criteria for secondary cytoreductive surgery (SCS) in recurrent ovarian cancer are yet to be defined. The aim of this study was to propose the selection criteria through identifying predictive factors for successful SCS.

Methods

All patients who underwent SCS for recurrent epithelial ovarian, tubal, and peritoneal cancers between 1982 and 2012 at our institution were identified through our database. Potential prognostic factors were evaluated in univariate and multivariate analyses. Survival after SCS was examined by the grouping model based on the number of prognostic factors.

Results

We performed SCS in 80 consecutive patients, 48 (60 %) of whom achieved complete resection. Complete/incomplete resection significantly influenced survival (median 65 vs. 26 months; p = 0.0005). Among favorable prognostic factors determined before SCS, treatment-free interval >12 months, absent distant metastasis, solitary disease, and performance status 0 were independently associated with better survival (p = 0.0009, 0.00003, 0.0004, and 0.015, respectively). Patients with 3–4 of those factors had better survival than those with 2 or 0–1 factors (median 79, 26, and 19 months; p < 0.00001 and <0.0000000001, respectively). Complete resection of visible tumors was achieved in 79 % of patients with 3–4 factors, in 40 % of those with 2 factors, and in 33 % of those with 0–1 factor. Importantly, even when tumor removal was incomplete at SCS, median survival of patients with 3–4 factors was still quite favorable (83 vs. 67.5 months for complete/incomplete resection, respectively), while those of patients with 2 factors (41 vs. 25 months) and 0–1 factor (19 vs. 19 months) were not.

Conclusion

We strongly recommend SCS for patients with 3–4 of the above favorable factors at recurrence. As for patients with 2 factors, SCS may be considered if complete resection is expected to be achieved. Prospective studies are warranted to validate our proposal.
Literatur
1.
Zurück zum Zitat Stuart GC, Kitchener H, Bacon M et al (2011) 2010 Gynecologic Cancer Inter Group (GCIG) consensus statement on clinical trials in ovarian cancer: report from the fourth ovarian cancer consensus conference. Int J Gynecol Cancer 21:750–755CrossRefPubMed Stuart GC, Kitchener H, Bacon M et al (2011) 2010 Gynecologic Cancer Inter Group (GCIG) consensus statement on clinical trials in ovarian cancer: report from the fourth ovarian cancer consensus conference. Int J Gynecol Cancer 21:750–755CrossRefPubMed
2.
Zurück zum Zitat Onda T, Yoshikawa H, Yasugi T et al (2005) Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma: proposal for patients selection. Br J Cancer 92:1026–1032CrossRefPubMedPubMedCentral Onda T, Yoshikawa H, Yasugi T et al (2005) Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma: proposal for patients selection. Br J Cancer 92:1026–1032CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Parmar MK, Ledermann JA, Colombo N et al (2003) Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361:2099–2106CrossRefPubMed Parmar MK, Ledermann JA, Colombo N et al (2003) Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361:2099–2106CrossRefPubMed
4.
Zurück zum Zitat Wagner U, Marth C, Largillier R et al (2012) Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. Br J Cancer 107:588–591CrossRefPubMedPubMedCentral Wagner U, Marth C, Largillier R et al (2012) Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. Br J Cancer 107:588–591CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Aghajanian C, Blank SV, Goff BA et al (2012) OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 30:2039–2045CrossRefPubMedPubMedCentral Aghajanian C, Blank SV, Goff BA et al (2012) OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 30:2039–2045CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Harter P, Heitz F, du Bois A et al (2012) Surgery for relapsed ovarian cancer: when should it be offered? Curr Oncol Rep. 14:539–543CrossRefPubMed Harter P, Heitz F, du Bois A et al (2012) Surgery for relapsed ovarian cancer: when should it be offered? Curr Oncol Rep. 14:539–543CrossRefPubMed
7.
Zurück zum Zitat Harter P, du Bois A, Hahmann M et al (2006) Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol 13:1702–1710CrossRefPubMed Harter P, du Bois A, Hahmann M et al (2006) Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol 13:1702–1710CrossRefPubMed
8.
Zurück zum Zitat Sehouli J, Richter R, Braicu EI et al (2010) Role of secondary cytoreductive surgery in ovarian cancer relapse: who will benefit? a systematic analysis of 240 consecutive patients. J Surg Oncol 102:656–662CrossRefPubMed Sehouli J, Richter R, Braicu EI et al (2010) Role of secondary cytoreductive surgery in ovarian cancer relapse: who will benefit? a systematic analysis of 240 consecutive patients. J Surg Oncol 102:656–662CrossRefPubMed
9.
Zurück zum Zitat Oksefjell H, Sandstad B, Trope C (2009) The role of secondary cytoreduction in the management of the first relapse in epithelial ovarian cancer. Ann Oncol 20:286–293CrossRefPubMed Oksefjell H, Sandstad B, Trope C (2009) The role of secondary cytoreduction in the management of the first relapse in epithelial ovarian cancer. Ann Oncol 20:286–293CrossRefPubMed
10.
Zurück zum Zitat Tian WJ, Jiang R, Cheng X et al (2010) Surgery in recurrent epithelial ovarian cancer: benefits on survival for patients with residual disease of 0.1–1 cm after secondary cytoreduction. J Surg Oncol 101:244–250PubMed Tian WJ, Jiang R, Cheng X et al (2010) Surgery in recurrent epithelial ovarian cancer: benefits on survival for patients with residual disease of 0.1–1 cm after secondary cytoreduction. J Surg Oncol 101:244–250PubMed
11.
Zurück zum Zitat Zang RY, Li ZT, Tang J et al (2004) Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits? Cancer 100:1152–1161CrossRefPubMed Zang RY, Li ZT, Tang J et al (2004) Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits? Cancer 100:1152–1161CrossRefPubMed
12.
Zurück zum Zitat Zang RY, Harter P, Chi DS et al (2011) Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort. Br J Cancer 105:890–896CrossRefPubMedPubMedCentral Zang RY, Harter P, Chi DS et al (2011) Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort. Br J Cancer 105:890–896CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Eisenkop SM, Friedman RL, Spirtos NM (2000) The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer 88:144–153CrossRefPubMed Eisenkop SM, Friedman RL, Spirtos NM (2000) The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer 88:144–153CrossRefPubMed
14.
Zurück zum Zitat Chi DS, McCaughty K, Diaz JP et al (2006) Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer 106:1933–1939CrossRefPubMed Chi DS, McCaughty K, Diaz JP et al (2006) Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer 106:1933–1939CrossRefPubMed
15.
Zurück zum Zitat Harter P, Sehouli J, Reuss A et al (2011) Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the multicenter intergroup study DESKTOP II. A project of the AGO kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. Int J Gynecol Cancer 21:289–295CrossRefPubMed Harter P, Sehouli J, Reuss A et al (2011) Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the multicenter intergroup study DESKTOP II. A project of the AGO kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. Int J Gynecol Cancer 21:289–295CrossRefPubMed
Metadaten
Titel
Proposal for selection criteria of secondary cytoreductive surgery in recurrent epithelial ovarian, tubal, and peritoneal cancers
verfasst von
Takeo Minaguchi
Toyomi Satoh
Koji Matsumoto
Manabu Sakurai
Hiroyuki Ochi
Mamiko Onuki
Akinori Oki
Hiroyuki Yoshikawa
Publikationsdatum
16.10.2015
Verlag
Springer Japan
Erschienen in
International Journal of Clinical Oncology / Ausgabe 3/2016
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-015-0910-8

Weitere Artikel der Ausgabe 3/2016

International Journal of Clinical Oncology 3/2016 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.